↓ Skip to main content

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

Overview of attention for article published in New England Journal of Medicine, October 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • Good Attention Score compared to outputs of the same age and source (72nd percentile)

Citations

dimensions_citation
628 Dimensions

Readers on

mendeley
450 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Published in
New England Journal of Medicine, October 2015
DOI 10.1056/nejmoa1412679
Pubmed ID
Authors

Philip J Mease, Iain B McInnes, Bruce Kirkham, Arthur Kavanaugh, Proton Rahman, Désirée van der Heijde, Robert Landewé, Peter Nash, Luminita Pricop, Jiacheng Yuan, Hanno B Richards, Shephard Mpofu

Abstract

Background In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety of secukinumab, an anti-interleukin-17A monoclonal antibody, in such patients. Methods In this double-blind, phase 3 study, 606 patients with psoriatic arthritis were randomly assigned in a 1:1:1 ratio to receive intravenous secukinumab (at a dose of 10 mg per kilogram) at weeks 0, 2, and 4, followed by subcutaneous secukinumab at a dose of either 150 mg or 75 mg every 4 weeks, or placebo. Patients in the placebo group were switched to subcutaneous secukinumab at a dose of 150 mg or 75 mg at week 16 or 24, depending on clinical response. The primary end point was the proportion of patients with an American College of Rheumatology 20 (ACR20) response at week 24, defined as a 20% improvement from baseline in the number of tender and swollen joints and at least three other important domains. Results ACR20 response rates at week 24 were significantly higher in the group receiving secukinumab at doses of 150 mg (50.0%) and 75 mg (50.5%) than in those receiving placebo (17.3%) (P<0.001 for both comparisons with placebo). Secondary end points, including the ACR50 response and joint structural damage, were significantly better in the secukinumab groups than in the placebo group. Improvements were sustained through 52 weeks. Infections, including candida, were more common in the secukinumab groups. Throughout the study (mean secukinumab exposure, 438.5 days; mean placebo exposure, 128.5 days), four patients in the secukinumab groups had a stroke (0.6 per 100 patient-years; 95% confidence interval [CI], 0.2 to 1.5), and two had a myocardial infarction (0.3 per 100 patient-years; 95% CI, 0.0 to 1.0), as compared with no patients in the placebo group. Conclusions Secukinumab was more effective than placebo in patients with psoriatic arthritis, which validates interleukin-17A as a therapeutic target. Infections were more common in the secukinumab groups than in the placebo group. The study was neither large enough nor long enough to evaluate uncommon serious adverse events or the risks associated with long-term use. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT01392326 .).

X Demographics

X Demographics

The data shown below were collected from the profiles of 53 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 450 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 <1%
United States 2 <1%
Canada 1 <1%
Brazil 1 <1%
Greece 1 <1%
Russia 1 <1%
Unknown 442 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 75 17%
Other 53 12%
Student > Ph. D. Student 47 10%
Student > Master 47 10%
Student > Bachelor 43 10%
Other 87 19%
Unknown 98 22%
Readers by discipline Count As %
Medicine and Dentistry 195 43%
Pharmacology, Toxicology and Pharmaceutical Science 30 7%
Biochemistry, Genetics and Molecular Biology 26 6%
Agricultural and Biological Sciences 25 6%
Immunology and Microbiology 20 4%
Other 37 8%
Unknown 117 26%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 108. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 February 2024.
All research outputs
#390,358
of 25,436,226 outputs
Outputs from New England Journal of Medicine
#5,724
of 32,493 outputs
Outputs of similar age
#5,341
of 286,991 outputs
Outputs of similar age from New England Journal of Medicine
#110
of 394 outputs
Altmetric has tracked 25,436,226 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,493 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 122.2. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,991 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 394 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.